Novo Nordisk’s Wegovy weight-loss pill surpassed 3 million U.S. prescriptions within five months of its January 5, 2026, launch. This milestone represents one of the most successful pharmaceutical launches by volume on record. The current pace has accelerated to one prescription filled approximately every five seconds.
More than 80% of these prescriptions belong to patients who have never used a GLP-1 therapy. This trend indicates the oral treatment is expanding the obesity market rather than cannibalizing existing injectable products.
The first million prescriptions required 12 weeks to complete. The subsequent two million prescriptions were filled in only 10 weeks. This shift underscores an accelerating adoption rate for the oral medication.